Bluebird’s Zynteglo Shows Long-Term Efficacy And Safety Amid US Commercialization Push

 
• By Alaric DeArment
  
Bluebird presented long-term data for Zynteglo at ASH 2022 • Source: Shutterstock

More from Gene Therapies

More from Advanced Therapies